Výsledky vyhledávání - "Mayur M. Amonkar"

Akademický článek

Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer

Autor: Mayur M. Amonkar, Monica Chase, Nicole M. Myer, Tongtong Wang, Vladimir Turzhitsky, Alexander Spira

Publikováno v: Cancer Treatment and Research Communications, Vol 36, Iss , Pp 100712- (2023)

Micro Abstract: This retrospective observational study assessed real-world treatment patterns and clinical outcomes among first-line MSI-H/dMMR metastatic colorectal cancer patients. Of 150 patients in the study cohort, 38.7% were treated with chemot

Externí odkaz: https://doaj.org/article/6d365d29da024c2e9759671b9448161c

Zobrazit plný text záznamu

Autor: Michele Maio, Mayur M. Amonkar, Josephine M. Norquist, Paolo A. Ascierto, Ludmila Manzyuk, Daniel Motola-Kuba, Nicolas Penel, Philippe A. Cassier, Giovanni M. Bariani, Ana De Jesus Acosta, Toshihiko Doi, Federico Longo, Wilson H. Miller, Do-Youn Oh, Maya Gottfried, Ruixue Wang, Kevin Norwood, Aurelien Marabelle

Publikováno v: European Journal of Cancer. 169:188-197

In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair‒deficient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dc198a9d43311914edaf6e290864b73
https://doi.org/10.1016/j.ejca.2022.03.040

Zobrazit plný text záznamu

Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis

Autor: Lauren A. Abderhalden, Ping Wu, Mayur M. Amonkar, Brian M. Lang, Sukrut Shah, Fan Jin, Andrew M. Frederickson, Ali Mojebi

Publikováno v: Journal of Gastrointestinal Cancer.

Purpose Although second-line treatments improve survival compared to best supportive care in patients with advanced gastric cancer with disease progression on first-line therapy, prognosis remains poor. A systematic review and meta-analysis were cond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46a33fbcbaefe6d9af5f16caf1e572f6
https://doi.org/10.1007/s12029-023-00932-5

Zobrazit plný text záznamu

Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis

Autor: Mayur M. Amonkar, Lauren A. Abderhalden, Andrew M. Frederickson, Audrone Aksomaityte, Brian M. Lang, Pierre Leconte, Ina Zhang

Publikováno v: International Journal of Colorectal Disease. 38

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6cab005ba5a0d638aa7628839cc7c37b
https://doi.org/10.1007/s00384-022-04301-9

Zobrazit plný text záznamu

DNA mismatch repair and microsatellite instability in colorectal tumors: An observational study in the Veterans Affairs Health Care System

Autor: Tongtong Wang, Justin D. Waller, Amy Wehn, Amanda De Hoedt, Stephen J. Freedland, Mayur M. Amonkar, Lin Gu, Zachary Klaassen, Kai-Li Liaw, Deepti Aurora-Garg, Daniel Albo

Publikováno v: Journal of Clinical Oncology. 39:e15562-e15562

e15562 Background: Microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR) cancers exhibit high mutational load and are observed in colorectal carcinomas (CRC). The objectives of this study were to determine the proportion of MSI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d6b96a3082a99ba5b51f772a5ebfa72
https://doi.org/10.1200/jco.2021.39.15_suppl.e15562

Zobrazit plný text záznamu

Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries

Autor: Katja Vouk, Ursula Benter, L Benjamin, A Marocco, Ceilidh Stapelkamp, Mayur M. Amonkar, Sylvie Pfersch

Publikováno v: Journal of Medical Economics. 19:900-912

Objective: To estimate per-event cost and economic burden associated with managing the most common and/or severe metastatic melanoma (MM) treatment-related adverse events (AEs) in Australia, France, Germany, Italy, and the UK. Methods: AEs associated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b6b9d6e8c72e2b1939a3e9c290f6dd1
https://doi.org/10.1080/13696998.2016.1184155

Zobrazit plný text záznamu

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Publikováno v: The Lancet Oncology. 16:1389-1398

In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba5b05e303e47c6db30c556a47fdfbb
https://doi.org/10.1016/s1470-2045(15)00087-x

Zobrazit plný text záznamu

Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population

Autor: Francis Vekeman, Michel Cloutier, Bhakti Arondekar, Mei Sheng Duh, Mayur M. Amonkar, S. Yermakov

Publikováno v: Melanoma Research. 24:602-610

Malignant melanoma patients frequently relapse with metastases in the brain, making it the third most common cancer-causing brain metastases in the USA. Management of brain metastases remains challenging because of the rapid progression of disease an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82bba511633f9ecd4eed08c1db78cc69
https://doi.org/10.1097/cmr.0000000000000097

Zobrazit plný text záznamu

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

Autor: Vanna Chiarion-Sileni, Michael Millward, J.-J. Grob, Kelly M. Grotzinger, Salvador Martín-Algarra, Boguslawa Karaszewska, Vicki L. Goodman, Lev V. Demidov, Mayur M. Amonkar, Suzanne Swann, Patricia Haney, E. Kämpgen, Wilson H. Miller, Axel Hauschild, Piotr Rutkowski, Cornelia Mauch, Beloo Mirakhur

Publikováno v: Annals of Oncology. 25:1428-1436

Background: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18–0.53; P < 0.0001) compared with dacarbazine (DTIC) i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3392c600a5ecb651cbc771db329dfec1
https://doi.org/10.1093/annonc/mdu154

Zobrazit plný text záznamu

Cost-Effectiveness of Lapatinib plus Letrozole in her2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer in Canada

Autor: Mayur M. Amonkar, Thomas E. Delea, Jordan Amdahl, Ayman Chit

Publikováno v: Current Oncology. 20:371-387

Background: The cost-effectiveness of first-line treatment with lapatinib plus letrozole for postmenopausal women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC) has n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::283d1e8d0062f60a699ba6674ec66441
https://doi.org/10.3747/co.20.1394

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání